|
|
Office Locations:
|
8755 W. Higgins Rd., Suite 1025
Chicago, IL 60631
Phone: 773-380-6600
Fax: 773-380-6606
| |
|
|
|
|
Information Technology
Life Sciences & Healthcare
|
|
|
Arch Venture Partners is a provider of seed and early-stage venture capital for technology firms with a special expertise in co-founding and building technology firms from startup. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH currently manages eight funds totaling nearly $2.0 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH Venture Partners became a private venture partnership after separating from its predecessor company, ARCH Development Corporation. Formed in 1986 by the Trustees of the University of Chicago, ARCH Development Corporation was managed by ARCH founding partners. The first fund, ARCH Venture Fund I, was a $9 million fund established in 1989. ARCH announced August 2014 that its eighth venture fund closed with more than $400 million in subscriptions. ARCH Venture Fund VIII exceeded its $250 million subscription target by more than $150 million. ARCH will invest $50K to $150M in a single deal. ARCH Venture Partners announced (June of 2022) the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. This new fund follows the January 2021 announcement of the $1.941 Billion ARCH Venture Fund XI.
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
Carol Suh | |
| |
Partner | |
Clinton W. Bybee | |
| |
Co-founder and Managing Director, Emeritus | |
Keith L. Crandell | |
| |
Co-Founder and Managing Director | |
Kristina Burow | |
| |
Managing Director | |
Mark McDonnell | |
| |
Managing Director, CAO & CFO | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
11/07/2024
|
Seaport Therapeutics
|
MA
|
$225,000,000
|
Series B
|
10/22/2024
|
Be Biopharma
|
MA
|
$82,000,000
|
Venture
|
10/17/2024
|
eGenesis
|
MA
|
$191,000,000
|
Series D
|
09/04/2024
|
ArsenalBio
|
CA
|
$325,000,000
|
Series C
|
08/15/2024
|
Quantum Circuits Inc
|
CT
|
$60,000,000
|
Series B
|
07/31/2024
|
AIRNA
|
MA
|
$90,000,000
|
Series A
|
06/05/2024
|
Advanced Medicine Partners
|
NC
|
$32,000,000
|
|
04/28/2024
|
Seaport Therapeutics
|
MA
|
$100,000,000
|
Series A
|
02/27/2024
|
Matter Neuroscience
|
CO
|
$26,000,000
|
Seed
|
02/13/2024
|
Areteia Therapeutics
|
NC
|
$75,000,000
|
Series A
|
02/01/2024
|
Proniras
|
WA
|
$4,650,000
|
Series B
|
02/01/2024
|
Basking Biosciences
|
OH
|
$55,000,000
|
Series B
|
01/23/2024
|
Elephas Biosciences
|
WI
|
$55,000,000
|
Series C
|
01/04/2024
|
Human Immunology Biosciences
|
CA
|
$95,000,000
|
Series B
|
|
|
|
|
|